BioSpace News Archive

Palatin today announced the initiation of a Phase 2b clinical trial with the melanocortin agonist, bremelanotide.

Novocure (NASDAQ: NVCR) today announced organizational changes to prepare for future growth, effective Jan. 17.

Pressure BioSciences, Inc. today announced results from initial consumer focus group testing of a THC Nanoemulsion Oral Spray prepared using PBI’s revolutionary Ultra Shear Technology platform.

Nautilus Biotechnology, Inc., a company pioneering a single-molecule protein analysis platform, and the Translational Genomics Research Institute, part of City of Hope, announced a partnership to explore the utility of the Nautilus platform by studying specific protein targets in diffuse intrinsic pontine glioma, a rare and often fatal childhood cancer.

Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced the publication of preclinical proof-of-concept data for its gene therapy candidate for Fabry disease, FLT190, in the Nature journal Gene Therapy.

Araris Biotech AG announced that Bernd Schlereth, Ph.D., chief development officer, will deliver an oral presentation at the 22nd annual PepTalk: Protein Science and Production Week being held January 16- 20, 2023 in San Diego.

Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) today announced that the U.S. Food and Drug Administration (FDA) has accepted Intercept’s New Drug Application (NDA) for obeticholic acid (OCA) seeking accelerated approval for the treatment of patients with pre-cirrhotic liver fibrosis due to nonalcoholic steatohepatitis (NASH).

Eurofins CellTx, an industry leader in regulated testing services for living donor eligibility testing, announced the official opening of its new laboratory in Tucson, AZ.

German medical device manufacturer PARI and smartShift, leading global provider of Intelligent Automation for SAP transformations based in Mannheim/Germany, announce their collaboration on the planned S/4HANA transformation for PARI group’s validated SAP systems.

Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the “Company” or “Sonnet”), a clinical-stage company developing targeted immunotherapeutic drugs, announced today that pharmacokinetic (PK) profile simulation of SON-1010 dosing has been completed in its randomized, placebo-controlled Phase 1 clinical trial in healthy volunteers.